CDR 202
Alternative Names: BI-771716; CDR-202Latest Information Update: 24 Jan 2025
At a glance
- Originator CDR-Life
- Developer Boehringer Ingelheim
- Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry macular degeneration
Most Recent Events
- 06 Jan 2025 Phase-II clinical trials in Dry macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT06722157)
- 05 Sep 2024 Boehringer Ingelheim plans a phase II trial for Dry macular degeneration in USA and Puerto Rico (Intravitreal) in December 2024 (NCT06722157)
- 05 Sep 2024 Adverse events data from a phase I trial in dry macular degeneration released by Boehringer Ingelheim